Trump’s Cuts to Medical Research Are Hurting These Stocks - Barron's
1. NIH cuts indirect funding affecting lab equipment firms significantly. 2. Illumina's shares dropped 15% amid concerns over NIH funding cuts. 3. NIH's 2025 budget reduces by 8%, impacting life science tools sector. 4. 25% of Illumina orders depend on NIH's indirect funding support. 5. NIH overhead cuts may jeopardize cancer research and industry stability.